


SUPPLEMENTAL MATERIAL

Hamerlik et al., <http://www.jem.org/cgi/content/full/jem.20111424/DC1>



**Figure S1.** FACS analysis of CD31, CD34, CD105, and CD144 endothelial markers in VEGFR2<sup>H</sup> GBM cells. (A) Examples of human cortical endothelial (HCEC) and/or peripheral white blood cells (HPWBC) are used as positive controls to document the functionality of the antibodies used, and thereby exclude false negative results with GBM cell populations. (B) Supplemental information to Fig. 1 and Fig. 2, showing no significant overlap of VEGFR2 and the aforementioned endothelial markers in two independent specimens tested (T556 and T1966).

**Table S1.** Tumor incidence and median survival

	Cell number	Incidence	Median survival
<b>T556</b>			
VEGFR2 low	100	2 out of 4	N.D.
	1,000	4 out of 4	34.5
	10,000	4 out of 4	24.0
VEGFR2 high	100	4 out of 4	43.0
	1,000	4 out of 4	24.0
	10,000	4 out of 4	24.0
<b>T1966</b>			
VEGFR2 low	100	3 out of 4	59.0
	1,000	4 out of 4	34.5
	10,000	4 out of 4	24.0
VEGFR2 high	100	4 out of 4	43.0
	1,000	4 out of 4	24.0
	10,000	4 out of 4	24.0